Zacks: Brokerages Anticipate Theravance Biopharma Inc (NASDAQ:TBPH) Will Post Quarterly Sales of $13.09 Million

Brokerages expect Theravance Biopharma Inc (NASDAQ:TBPH) to announce $13.09 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Theravance Biopharma’s earnings. The lowest sales estimate is $11.00 million and the highest is $14.80 million. Theravance Biopharma reported sales of $12.84 million in the same quarter last year, which indicates a positive year-over-year growth rate of 1.9%. The business is scheduled to issue its next earnings results on Tuesday, November 5th.

On average, analysts expect that Theravance Biopharma will report full year sales of $52.83 million for the current fiscal year, with estimates ranging from $45.78 million to $57.70 million. For the next fiscal year, analysts expect that the company will report sales of $97.99 million, with estimates ranging from $74.18 million to $129.80 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for Theravance Biopharma.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.72) EPS for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.50. Theravance Biopharma had a negative net margin of 369.67% and a negative return on equity of 2,631.71%. The business had revenue of $26.15 million for the quarter, compared to analysts’ expectations of $13.92 million.

A number of research analysts have commented on TBPH shares. Cantor Fitzgerald reiterated a “buy” rating and set a $55.00 price target on shares of Theravance Biopharma in a research report on Friday, April 12th. Piper Jaffray Companies set a $55.00 price target on shares of Theravance Biopharma and gave the company a “buy” rating in a research report on Wednesday. Finally, BidaskClub upgraded shares of Theravance Biopharma from a “hold” rating to a “buy” rating in a research report on Tuesday. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Theravance Biopharma currently has a consensus rating of “Buy” and a consensus target price of $44.25.

In other Theravance Biopharma news, Director Donal O’connor sold 4,000 shares of the stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $20.46, for a total transaction of $81,840.00. Following the transaction, the director now directly owns 30,244 shares in the company, valued at $618,792.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.60% of the stock is owned by company insiders.

Several institutional investors have recently modified their holdings of TBPH. Norges Bank bought a new position in shares of Theravance Biopharma in the fourth quarter worth approximately $22,422,000. Fosun International Ltd bought a new position in shares of Theravance Biopharma in the first quarter worth approximately $2,386,000. Geode Capital Management LLC grew its holdings in shares of Theravance Biopharma by 10.2% in the fourth quarter. Geode Capital Management LLC now owns 497,224 shares of the biopharmaceutical company’s stock worth $12,723,000 after purchasing an additional 46,003 shares during the last quarter. Tibra Equities Europe Ltd bought a new position in shares of Theravance Biopharma in the first quarter worth approximately $660,000. Finally, D. E. Shaw & Co. Inc. grew its holdings in shares of Theravance Biopharma by 46.7% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 75,034 shares of the biopharmaceutical company’s stock worth $1,920,000 after purchasing an additional 23,885 shares during the last quarter. Hedge funds and other institutional investors own 84.77% of the company’s stock.

NASDAQ TBPH traded down $0.50 on Monday, reaching $20.66. 320,049 shares of the company’s stock traded hands, compared to its average volume of 231,457. Theravance Biopharma has a 12 month low of $15.18 and a 12 month high of $35.48. The stock has a 50-day moving average price of $17.48. The firm has a market cap of $1.17 billion, a PE ratio of -5.18 and a beta of 1.74.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.

Further Reading: Why is momentum important to successful trading?

Get a free copy of the Zacks research report on Theravance Biopharma (TBPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.